Patent intelligence · US
US 10363293
Vaccine composition
Vaccine composition
Patent details — US 10363293
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 30, 2019
- Expiration
- Jul 25, 2039
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Claims
- 21
- CPC classes
- A61K, A61K2039/5254, A61K2039/5256, A61K2039/545
Quick answer
US 10363293 (Vaccine composition) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Jul 30, 2019. Expires Jul 25, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/5254, A61K2039/5256, A61K2039/545, A61K2039/55561, A61K2039/572
More from TURNSTONE LIMITED PARTNERSHIP
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Frequently asked questions
What is US patent 10363293?
US 10363293 (Vaccine composition) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Jul 30, 2019. Expires Jul 25, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10363293?
TURNSTONE LIMITED PARTNERSHIP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 10363293 expire?
Our index shows an expiration date of Jul 25, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.